Related Experiment Video
Updated: Feb 21, 2026
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
24.4K
Biomarkers of Colorectal Cancer Risk Decrease 6 months After Roux-en-Y Gastric Bypass Surgery
Sorena Afshar1,2, Fiona Malcomson3, Seamus B Kelly4
1Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Campus for Ageing and Vitality, Newcastle on Tyne, NE4 5PL, UK. S.Afshar@doctors.org.uk.
Obesity Surgery
|October 10, 2017
Summary
Roux-en-Y gastric bypass (RYGB) surgery in obese adults reduced colorectal cancer (CRC) risk markers. Weight loss improved glucose regulation and decreased inflammation and rectal cell proliferation, suggesting RYGB may lower CRC risk.
Area of Science:
- Bariatric Surgery
- Oncology
- Gastroenterology
Background:
- The relationship between weight loss and colorectal cancer (CRC) risk is unclear.
- Roux-en-Y gastric bypass (RYGB) surgery's effect on CRC risk requires further investigation.
Purpose of the Study:
- To assess the impact of RYGB on biomarkers associated with colorectal cancer (CRC) risk.
- To investigate changes in systemic inflammation, glucose homeostasis, and rectal mucosal gene expression post-RYGB.
Main Methods:
- Rectal biopsies and blood samples were collected from RYGB patients and controls.
- Systemic inflammation, glucose markers, rectal gene expression, and cell proliferation were analyzed pre- and post-surgery.
Main Results:
- RYGB led to significant weight loss (29 kg) and improved glucose regulation and systemic inflammation markers.
- Rectal mucosal pro-inflammatory gene expression did not increase, and COX-1 expression decreased.
- Rectal crypt cell proliferation significantly reduced post-RYGB.
Conclusions:
- RYGB surgery in obese adults reduced markers of tumorigenic potential.
- The study suggests surgically induced weight loss via RYGB may decrease colorectal cancer (CRC) risk.
